Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUAL V: Insulin Degludec/Liraglutide vs Glargine in T2DM
NCT01952145Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2013
- Primary completion
- Nov 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
A Phase 3 trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Sep 2013; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01952145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01952145.